Walleye Capital
OCUL icon

Walleye Capital’s Ocular Therapeutix OCUL Stock Holding History

Walleye Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Sell
201,782
-539,360
-73% -$4.89M 0.01% 1528
2026
Q1 		$6.28M Buy
741,142
+510,633
+222% +$4.87M 0.03% 657
2025
Q4 		$2.8M Buy
230,509
+169,668
+279% +$2.06M 0.01% 1590
2025
Q3 		$711K Buy
+60,841
New +$728K ﹤0.01% 2343
2025
Q1 		– Sell
-10,548
Closed -$90.1K – 4869
2024
Q4 		$90.1K Buy
+10,548
New +$103K ﹤0.01% 4180
2024
Q2 		– Sell
-82,058
Closed -$747K – 5873
2024
Q1 		$747K Buy
+82,058
New +$582K ﹤0.01% 2855
2023
Q3 		– Sell
-43,665
Closed -$225K – 5190
2023
Q2 		$225K Buy
43,665
+24,854
+132% +$148K ﹤0.01% 3006
2023
Q1 		$99.1K Buy
+18,811
New +$89.3K ﹤0.01% 2935
2022
Q2 		– Sell
-15,482
Closed -$77K – 2617
2022
Q1 		$77K Sell
15,482
-55,973
-78% -$310K ﹤0.01% 1792
2021
Q4 		$498K Buy
+71,455
New +$555K 0.02% 987
2020
Q3 		– Sell
-34,700
Closed -$289K – 931
2020
Q2 		$289K Buy
34,700
+23,700
+215% +$157K 0.06% 344
2020
Q1 		$55K Buy
+11,000
New +$54.3K 0.01% 678

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's OCUL Position: Q2 2026 in Review

Walleye Capital reduced its Ocular Therapeutix (OCUL) stake by 73% in Q2 2026, selling an estimated $4.89M and leaving 201,782 shares worth $1.98M. The position accounts for 0.01% of the portfolio, ranked #1528.

Walleye Capital first reported a position in OCUL in Q1 2020 and has held it in 12 quarters since. The position peaked at $6.28M in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Walleye Capital held 201,782 shares of Ocular Therapeutix worth $1.98M as of Q2 2026.
  • Walleye Capital sold 539,360 Ocular Therapeutix shares in Q2 2026, an estimated $4.89M.
  • Ocular Therapeutix made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1528 holding.
  • Walleye Capital first reported a position in Ocular Therapeutix in Q1 2020 and has held it in 12 quarters since.
  • Walleye Capital's Ocular Therapeutix position peaked at $6.28M in Q1 2026.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.